[
  {
    "ts": "2025-12-04T13:10:13+00:00",
    "headline": "Vertex Pharmaceuticals (VRTX): Assessing Valuation After Recent Multi-Month Share Price Gains",
    "summary": "Vertex Pharmaceuticals (VRTX) has quietly added to recent gains, with shares up around 10% over the past month and roughly 17% in the past 3 months, drawing fresh attention to its long term growth story. See our latest analysis for Vertex Pharmaceuticals. At around $463 per share, Vertex’s recent 1 month share price return of nearly 10% and 3 month share price return of about 17% signal building momentum on the back of steady pipeline progress and solid earnings growth, supported by a robust...",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-assessing-valuation-131013483.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "76bbf2fe-e542-39f6-85b8-902a50c93874",
      "content": {
        "id": "76bbf2fe-e542-39f6-85b8-902a50c93874",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals (VRTX): Assessing Valuation After Recent Multi-Month Share Price Gains",
        "description": "",
        "summary": "Vertex Pharmaceuticals (VRTX) has quietly added to recent gains, with shares up around 10% over the past month and roughly 17% in the past 3 months, drawing fresh attention to its long term growth story. See our latest analysis for Vertex Pharmaceuticals. At around $463 per share, Vertex’s recent 1 month share price return of nearly 10% and 3 month share price return of about 17% signal building momentum on the back of steady pipeline progress and solid earnings growth, supported by a robust...",
        "pubDate": "2025-12-04T13:10:13Z",
        "displayTime": "2025-12-04T13:10:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihFoSuY9PLXURl2kI_sV.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bIz6sh0rX4c7ACsVP8z51w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-assessing-valuation-131013483.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-assessing-valuation-131013483.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-04T14:34:16+00:00",
    "headline": "Harding Loevner Global Equity’s Views on Vertex Pharmaceuticals Incorporated (VRTX)",
    "summary": "Harding Loevner, an asset management company, released its “Global Equity Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.62% gross (2.52% net) in the third quarter of 2025, compared to a 7.74% return for the MSCI All Country World Index and 7.36% gain for the MSCI […]",
    "url": "https://finance.yahoo.com/news/harding-loevner-global-equity-views-143416421.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "1b064c05-23cf-3cbc-8367-f7e3bb1a4a44",
      "content": {
        "id": "1b064c05-23cf-3cbc-8367-f7e3bb1a4a44",
        "contentType": "STORY",
        "title": "Harding Loevner Global Equity’s Views on Vertex Pharmaceuticals Incorporated (VRTX)",
        "description": "",
        "summary": "Harding Loevner, an asset management company, released its “Global Equity Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.62% gross (2.52% net) in the third quarter of 2025, compared to a 7.74% return for the MSCI All Country World Index and 7.36% gain for the MSCI […]",
        "pubDate": "2025-12-04T14:34:16Z",
        "displayTime": "2025-12-04T14:34:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/d61abed3f7567688cd16b4e2785171ec",
          "originalWidth": 768,
          "originalHeight": 430,
          "caption": "Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/73o67FZt31QGX4RW9oCwEA--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d61abed3f7567688cd16b4e2785171ec.cf.webp",
              "width": 768,
              "height": 430,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eKC281F2zJCXGmB_sO5saA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d61abed3f7567688cd16b4e2785171ec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/harding-loevner-global-equity-views-143416421.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/harding-loevner-global-equity-views-143416421.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]